Nynikka Palmer, DrPH, MPH

Title(s)Associate Professor, Medicine
SchoolSchool of Medicine
Address2540 23rd Street, #4707
San Francisco CA 94110
PronounsShe/Her/Hers
ORCID ORCID Icon0000-0002-5311-447X Additional info
vCardDownload vCard

    Collapse Biography 
    Collapse Education and Training
    Wake Forest School of MedicinePostdoctoral Fellowship2013Cancer Survivorship
    University of Texas Health Science CenterDrPH2010School of Public Health
    Emory UniversityMPH2002Rollins School of Public Health
    Morgan State UniversityBS2000
    Collapse Awards and Honors
    National Institutes of Health – National Institute on Minority Health and Health Disparities2021  - 2023Health Disparities Research Loan Repayment Program Award.
    University of California San Francisco2018School of Medicine Inaugural Class of Dean’s Population Health and Healthy Equity (PHHE) Scholars
    National Institutes of Health – National Institute on Minority Health and Health Disparities2016  - 2017Health Disparities Research Loan Repayment Program
    University of California San Francisco2016  - 2017CTSI KL2 Scholar Award
    University of California San Francisco2016Helen Diller Family Chair in Community Education and Outreach for Urologic Cancer
    University of California San Francisco2015  - 2016Center for Aging in Diverse Communities Scholar Award
    University of California San Francisco2015Distinguished Honoree of the Black Student Health Alliance - 2nd Annual African Heritage Celebration
    National Institute on Minority Health and Health Disparities - National Institutes of Health2013  - 2015Health Disparities Research Loan Repayment Program

    Collapse Overview 
    Collapse Overview
    Dr. Palmer is an Associate Professor at the University of California San Francisco (UCSF), in the Division of General Internal Medicine at Zuckerberg San Francisco General Hospital, with secondary appointments in the Departments of Urology and Radiation Oncology. She has a long history and commitment to health equity research. Her research focuses on unraveling the mechanisms of cancer disparities in high-quality cancer care and health outcomes among African Americans, with a depth of knowledge in cultural influence, patient-centered care and communication, and strategies that enhance delivery of high-quality cancer care. Community engagement is the foundation of her work and she strongly believes in the adage, “nothing about me without me,” as patients’ and communities’ perspectives are essential to advance research and optimize health care.

    Dr. Palmer currently has a National Cancer Institute-funded career development award to bridge the divide between low-income African American men and equal prostate cancer (PCa) treatment by anchoring the evidence-based intervention of peer navigation in the relational concept of African American brotherhood as a means to foster trust and empowerment, and optimize patient-centered communication and quality of care. She has led and collaborated on various research projects on PCa and patient-provider communication, including a scoping review to characterize the growing body of literature on postoperative patient-initiated communication after hospital discharge. She is co-leader of the Prostate Cancer Task Force of the San Francisco Cancer Initiative (SF CAN), which aims to eliminate PCa disparities among African American men through community and healthcare system engagement to advance education, ensure early detection and appropriate follow-up of aggressive disease, implement navigation and support services, and engage in multiple institutional partnerships that ensure high-quality care throughout the city and county of San Francisco. To promote PCa survivorship, empowerment and patient engagement, she established and oversees two support groups in the San Francisco Bay Area for African American men facing PCa – one that has been thriving since September 2014 and another that was launched January 2020. Several group participants also serve as advisors to her ongoing research program.

    Collapse Research 
    Collapse Research Activities and Funding
    PACE Yourself: Optimizing Patient- Centered Communication for Prostate Cancer Care in the Safety-Net
    Mike Slive Foundation for Prostate Cancer Research's pilot grant program Jan 1, 2023 - Dec 31, 2023
    Role: PI
    Description: We propose the development of an electronic communication tool for providers and a patient resource, called PAtient-CEntered (PACE) Yourself, to help guide prostate cancer providers (urologists and radiation oncologists) to clearly communicate a prostate cancer diagnosis, prognosis, treatment options and side effects, and next steps with newly diagnosed prostate cancer patients in safety-net settings; and connect underserved patients with resources that can guide them along a journey to equitable healthcare and survivorship. We aim to (1) create an initial prototype of PACE Yourself developed in collaboration with a design team, and (2) pilot test and revise the prototype to build an electronic form within the electronic health record.
    An Atlas of Human Prostate Across Ancestries
    Chan Zuckerberg Initiative (Advised fund of the Silicon Valley Community Foundation) P0559192Dec 1, 2021 - Nov 30, 2024
    Role: PI of Community Engagement
    Description: Our project aims to develop a comprehensive atlas of the human prostate at single-cell resolution with a community engagement plan to maximize impact for the public, clinical and scientific communities. This project will leverage state-of-the-art techniques to characterize cellular heterogeneity across ancestries and ages in the normal prostate. We will define the transcriptomic, epigenomic, and spatial features of prostate cell types from younger to older men across ancestrally diverse groups. Our study will lead a community engagement approach that will inform a “cells to society” framework to maximize the impact of our finds and educate the community and public on the role that cells play in healthy tissue and disease.
    HERE with Community (Health Equity REsearch with Community health centers)
    PCORI – Patient-Centered Outcomes Research Institute P0554210 [CA-0184403]Oct 22, 2021 - Apr 21, 2023
    Role: Dual-PI
    Description: Catalyzing Systematic Stakeholder Engagement between Academic and Community Health Centers for COVID-19 PCOR and CER. Our project will create effective, efficient, and sustainable infrastructure and systematic processes that builds capacity to operationalize stakeholder engagement for health equity focused patient-centered outcomes research (PCOR) and comparative effectiveness research (CER) addressing COVID-19 topics between academic and community health centers.
    Accelerating Systematic Stakeholder, Patient, and Institution Research Engagement (ASPIRE)
    PCORI – Patient-Centered Outcomes Research Institute 10566-UCSFOct 2, 2018 - May 14, 2021
    Role: Program Development and Evaluation
    Description: ASPIRE aims to create academic institutional infrastructures that support and promote patient-centered outcomes research (PCOR) with maximal efficiency and impact. We seek to understand the stakeholder needs for PCOR investigators and build capacity for systematic stakeholder engagement by linking to infrastructures created by CTSIs and other infrastructures that already exist in academic institutions. This includes a supplement (05/15/2020–05/14/2021) focused on a sub-committee of the ASPIRE Board to review and provide feedback on research directly related to COVID-19 at UCSF.
    Constructing a Relational Bridge to Achieve High-Quality Prostate Cancer Care for African Americans
    NIH K01CA211965Sep 1, 2017 - Aug 31, 2022
    Role: Principal Investigator
    Description: This study aims to mitigate the perfect storm of complex treatment options and constraints in communication by constructing a relational bridge between low-income African American men and equal prostate cancer care, using peer navigation to foster trust and empowerment and optimize communication and quality of care.

    Collapse Featured Content 
    Collapse Twitter

    Collapse Bibliographic 
    Collapse Publications
    Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Researchers can login to make corrections and additions, or contact us for help. to make corrections and additions.
    Newest   |   Oldest   |   Most Cited   |   Most Discussed   |   Timeline   |   Field Summary   |   Plain Text
    Altmetrics Details PMC Citations indicate the number of times the publication was cited by articles in PubMed Central, and the Altmetric score represents citations in news articles and social media. (Note that publications are often cited in additional ways that are not shown here.) Fields are based on how the National Library of Medicine (NLM) classifies the publication's journal and might not represent the specific topic of the publication. Translation tags are based on the publication type and the MeSH terms NLM assigns to the publication. Some publications (especially newer ones and publications not in PubMed) might not yet be assigned Field or Translation tags.) Click a Field or Translation tag to filter the publications.
    1. Building a Client Resource and Communication Platform for Community-Based Organizations to Address Health and Social Needs: Co-Design Study. JMIR Hum Factors. 2024 Aug 16; 11:e53939. Lyles C, Berrean B, Buenaventura A, Milter S, Hernandez DD, Sarkar U, Gutierrez C, Palmer N, Brown Iii W. PMID: 39157908; PMCID: PMC11342060.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    2. PD19-05 SMARTER SCREENING AND TREATMENT (S3T): MITIGATING HARM VIA AGE- & BASELINE-PROSTATE SPECIFIC ANTIGEN-STRATIFIED SCREENING. Journal of Urology. 2024 May 1; 211(5S):e441. Nie NJ, Palmer PN, Pasick PR, Byron BM, de la Calle dC, Washington WS, Kivlahan KC, Potter PM, Cooperberg CM. .
      View in: Publisher Site   Mentions:
    3. Engaging communities to inform the development of a diverse cohort of cancer survivors: formative research for the eat move sleep study (EMOVES). Res Involv Engagem. 2023 Dec 11; 9(1):117. Andemeskel G, Palmer NR, Pasick R, Van Blarigan EL, Kenfield SA, Graff RE, Shaw M, Yu W, Sanchez M, Hernandez R, Washington SL, Shariff-Marco S, Rhoads KF, Chan JM. PMID: 38082391; PMCID: PMC10712178.
      View in: PubMed   Mentions:
    4. Ten-year work burden after prostate cancer treatment. Cancer Med. 2023 Sep; 12(18):19234-19244. Washington SL, Lonergan PE, Cowan JE, Zhao S, Broering JM, Palmer NR, Hicks C, Cooperberg MR, Carroll PR. PMID: 37724617; PMCID: PMC10557888.
      View in: PubMed   Mentions: 1     Fields:    
    5. The Impact of Patient-Physician Racial and Gender Concordance on Patient Satisfaction with Outpatient Clinic Visits. J Racial Ethn Health Disparities. 2024 Aug; 11(4):2083-2092. Shaw NM, Hills N, Holler J, Fernandez A, Davis D, Palmer NR, Sliwka D, Breyer BN. PMID: 37341950.
      View in: PubMed   Mentions: 1     Fields:    Translation:Humans
    6. Best Current Practice and Research Priorities in Active Surveillance for Prostate Cancer-A Report of a Movember International Consensus Meeting. Eur Urol Oncol. 2023 04; 6(2):160-182. Moore CM, King LE, Withington J, Amin MB, Andrews M, Briers E, Chen RC, Chinegwundoh FI, Cooperberg MR, Crowe J, Finelli A, Fitch MI, Frydenberg M, Giganti F, Haider MA, Freeman J, Gallo J, Gibbs S, Henry A, James N, Kinsella N, Lam TBL, Lichty M, Loeb S, Mahal BA, Mastris K, Mitra AV, Merriel SWD, van der Kwast T, Van Hemelrijck M, Palmer NR, Paterson CC, Roobol MJ, Segal P, Schraidt JA, Short CE, Siddiqui MM, Tempany CMC, Villers A, Wolinsky H, MacLennan S. PMID: 36710133.
      View in: PubMed   Mentions: 9     Fields:    Translation:Humans
    7. Opportunities and challenges in discussing racism during primary care visits. Health Serv Res. 2023 04; 58(2):282-290. Borowsky HM, Willis A, Bullock JL, Fuentes-Afflick E, Palmer NRA. PMID: 36524295; PMCID: PMC10012223.
      View in: PubMed   Mentions: 2     Fields:    Translation:Humans
    8. Navigation programs relevant for African American men with prostate cancer: a scoping review protocol. Syst Rev. 2022 06 14; 11(1):122. Palmer NR, Smith AN, Campbell BA, Andemeskel G, Tahir P, Felder TM, Cicerelli B. PMID: 35701771; PMCID: PMC9195379.
      View in: PubMed   Mentions: 1     Fields:    Translation:Humans
    9. Addressing the challenges of conducting community-engaged research during COVID-19: Rapid development and evaluation of a COVID-19 Research Patient and Community Advisory Board (PCAB). J Clin Transl Sci. 2022; 6(1):e88. Harrison JD, Palmer NRA, Cabrera A, Fleisher P, Wong E, LeSarre M, Grumbach K, Banta J, Tealer L, Reynolds A, Wassmann A, Rose T, Nguyen T. PMID: 35989858; PMCID: PMC9379936.
      View in: PubMed   Mentions: 1  
    10. MP28-10 10-YEAR OUTCOMES IN WORK LOSS, PHYSICAL FUNCTION, AND MENTAL HEALTH OF 6,693 MEN UNDERGOING PRIMARY TREATMENT FOR PROSTATE CANCER. Investigative Urology. 2022 May 1; 207(Supplement 5):e464. Washington WS, Lonergan LP, Cowan CJ, Zhao ZS, Greenberg GS, Broering BJ, Palmer PN, Parker PR, Bell BA, Cooperberg CM, Carroll CP. .
      View in: Publisher Site   Mentions:
    11. Mobile Clinical Trial Matching Technology in Medical Oncology Clinic: A Pilot Feasibility Study. JCO Clin Cancer Inform. 2022 05; 6:e2100182. Borno HT, Zhang L, Zhang S, Kaplan C, Palmer NR, Bell A, Bakke B, Lin A, Aggarwal R, Small EJ. PMID: 35584338; PMCID: PMC9173564.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    12. From Cancer Epidemiology to Policy and Practice: the Role of a Comprehensive Cancer Center. Curr Epidemiol Rep. 2022; 9(1):10-21. Hiatt RA, Sibley A, Venkatesh B, Cheng J, Dixit N, Fox R, Ling P, Nguyen T, Oh D, Palmer NR, Pasick RJ, Potter MB, Somsouk M, Vargas RA, Vijayaraghavan M, Ashworth A. PMID: 35342686; PMCID: PMC8935108.
      View in: PubMed   Mentions: 3  
    13. Evaluating the impact of financial toxicity among cancer clinical trial participants. International Journal of Cancer Care and Delivery. 2022 Jan 3. Borno BH, Zhang ZS, Lin LT, Zhang ZL, Palmer PN, Nguyen NC, Kaplan KC, Ryan RC. .
      View in: Publisher Site   Mentions:
    14. Access and Representation: A Narrative Review of the Disparities in Access to Clinical Trials and Precision Oncology in Black men with Prostate Cancer. Urology. 2022 05; 163:90-98. Esdaille AR, Ibilibor C, Holmes A, Palmer NR, Murphy AB. PMID: 34582887.
      View in: PubMed   Mentions: 6     Fields:    Translation:Humans
    15. MP19-14 LONGITUDINAL ANALYSIS OF THE INDIRECT BURDEN OF PROSTATE CANCER TREATMENT ON PAID AND UNPAID WORK: DATA FROM CAPSURE. Investigative Urology. 2021 Sep 1; 206(Supplement 3). Washington WS, Lonergan LP, Cowan CJ, Zhao ZS, Greenberg GS, Broering BJ, Palmer PN, Parker PR, Bell BA, Cooperberg CM, Carroll CP. .
      View in: Publisher Site   Mentions:
    16. A Cross-Sectional Analysis of Barriers Associated With Non-Attendance at a Urology Telehealth Clinic in a Safety-Net Hospital. Urology. 2022 04; 162:57-62. Bell A, Lonergan PE, Escobar D, Fakunle M, Chu CE, Berdy S, Palmer NR, Breyer BN, Washington SL. PMID: 34461145.
      View in: PubMed   Mentions: 4     Fields:    Translation:HumansPHPublic Health
    17. Abstract 686: Longitudinal analysis of the indirect burden of prostate cancer management on paid and unpaid work: Data from CaPSURE database. Cancer Research. 2021 Jul 1; 81(13_Supplement):686-686. Washington WS, Lonergan LP, Cowan CJ, Zhao ZS, Greenberg GS, Broering BJ, Palmer PN, Cooperberg CM, Carroll CP. .
      View in: Publisher Site   Mentions:
    18. Prostate cancer patients' self-reported participation in research: an examination of racial/ethnic disparities. Cancer Causes Control. 2021 Oct; 32(10):1161-1172. Palmer NR, Borno HT, Gregorich SE, Livaudais-Toman J, Kaplan CP. PMID: 34189651; PMCID: PMC8416807.
      View in: PubMed   Mentions: 1     Fields:    Translation:Humans
    19. Redefining Attribution From Patient to Health System-How the Notion of "Mistrust" Places Blame on Black Patients. JAMA Oncol. 2021 05 01; 7(5):780. Borno HT, Andemeskel G, Palmer NR. PMID: 33662096.
      View in: PubMed   Mentions: 5     Fields:    
    20. Post-Diagnostic Dietary and Lifestyle Factors and Prostate Cancer Recurrence, Progression, and Mortality. Curr Oncol Rep. 2021 03 10; 23(3):37. Langlais CS, Graff RE, Van Blarigan EL, Palmer NR, Washington SL, Chan JM, Kenfield SA. PMID: 33689041; PMCID: PMC7946660.
      View in: PubMed   Mentions: 25     Fields:    Translation:HumansPHPublic Health
    21. Earning the Trust of African American Communities to Increase Representation in Dementia Research. Innovation in Aging. 2020 Dec 16; 4(Suppl 1):878-878. Portacolone PE, Palmer PN, Lichtenberg LP, Waters WC, Hill HC, Keiser KS, Johnson JJ. .
      View in: Publisher Site   Mentions:
    22. Earning the Trust of African American Communities to Increase Representation in Dementia Research. Ethn Dis. 2020; 30(Suppl 2):719-734. Portacolone E, Palmer NR, Lichtenberg P, Waters CM, Hill CV, Keiser S, Vest L, Maloof M, Tran T, Martinez P, Guerrero J, Johnson JK. PMID: 33250619; PMCID: PMC7683027.
      View in: PubMed   Mentions: 19     Fields:    Translation:Humans
    23. "Can you hear me now?": postoperative patient-initiated communication with providers. Am J Manag Care. 2020 10 01; 26(10):e333-e341. Balakrishnan AS, Palmer NR, Odisho AY. PMID: 33094946.
      View in: PubMed   Mentions: 3     Fields:    Translation:Humans
    24. Cancer health disparities in racial/ethnic minorities in the United States. Br J Cancer. 2021 01; 124(2):315-332. Zavala VA, Bracci PM, Carethers JM, Carvajal-Carmona L, Coggins NB, Cruz-Correa MR, Davis M, de Smith AJ, Dutil J, Figueiredo JC, Fox R, Graves KD, Gomez SL, Llera A, Neuhausen SL, Newman L, Nguyen T, Palmer JR, Palmer NR, Pérez-Stable EJ, Piawah S, Rodriquez EJ, Sanabria-Salas MC, Schmit SL, Serrano-Gomez SJ, Stern MC, Weitzel J, Yang JJ, Zabaleta J, Ziv E, Fejerman L. PMID: 32901135; PMCID: PMC7852513.
      View in: PubMed   Mentions: 295     Fields:    Translation:Humans
    25. Ethnographic investigation of patient-provider communication among African American men newly diagnosed with prostate cancer: a study protocol. BMJ Open. 2020 08 05; 10(8):e035032. Palmer NR, Shim JK, Kaplan CP, Schillinger D, Blaschko SD, Breyer BN, Pasick RJ. PMID: 32759241; PMCID: PMC7409964.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    26. Abstract A047: An ethnographic study of African American men's prostate cancer treatment decision-making. Cancer Epidemiology Biomarkers & Prevention. 2020 Jun 1; 29(6_Supplement_1):a047-a047. Palmer PN, Street SR, Schillinger SD, Shim SJ, Blaschko BS, Breyer BB, Pasick PR. .
      View in: Publisher Site   Mentions:
    27. Rural cancer survivors' health information needs post-treatment. Patient Educ Couns. 2020 08; 103(8):1606-1614. Palmer NR, Avis NE, Fino NF, Tooze JA, Weaver KE. PMID: 32147307; PMCID: PMC7311274.
      View in: PubMed   Mentions: 13     Fields:    Translation:Humans
    28. Defining and Measuring Adherence in Observational Studies Assessing Outcomes of Real-world Active Surveillance for Prostate Cancer: A Systematic Review. Eur Urol Oncol. 2021 04; 4(2):192-201. Kith G, Lisker S, Sarkar U, Barr-Walker J, Breyer BN, Palmer NR. PMID: 31288992; PMCID: PMC6943197.
      View in: PubMed   Mentions: 2     Fields:    Translation:Humans
    29. Minority Recruitment Trends in Phase III Prostate Cancer Clinical Trials (2003 to 2014): Progress and Critical Areas for Improvement. J Urol. 2019 02; 201(2):259-267. Balakrishnan AS, Palmer NR, Fergus KB, Gaither TW, Baradaran N, Ndoye M, Breyer BN. PMID: 30218761.
      View in: PubMed   Mentions: 18     Fields:    Translation:Humans
    30. Differential use of medical versus surgical androgen deprivation therapy for patients with metastatic prostate cancer. Cancer. 2019 02 01; 125(3):453-462. Borno HT, Lichtensztajn DY, Gomez SL, Palmer NR, Ryan CJ. PMID: 30444526; PMCID: PMC6340740.
      View in: PubMed   Mentions: 7     Fields:    Translation:Humans
    31. A bilingual, Internet-based, targeted advertising campaign for prostate cancer clinical trials: Assessing the feasibility, acceptability, and efficacy of a novel recruitment strategy. Contemp Clin Trials Commun. 2018 Dec; 12:60-67. Kaplan CP, Siegel A, Leykin Y, Palmer NR, Borno H, Bielenberg J, Livaudais-Toman J, Ryan C, Small EJ. PMID: 30272035; PMCID: PMC6158958.
      View in: PubMed   Mentions: 5  
    32. Racial and Ethnic Differences in Prostate Cancer Survivors' Perceived Engagement in Treatment Decision-Making. J Racial Ethn Health Disparities. 2018 12; 5(6):1273-1283. Palmer NR, Gregorich SE, Livaudais-Toman J, Jih J, Kaplan CP. PMID: 29516434; PMCID: PMC6526935.
      View in: PubMed   Mentions: 6     Fields:    Translation:Humans
    33. The San Francisco Cancer Initiative: A Community Effort To Reduce The Population Burden Of Cancer. Health Aff (Millwood). 2018 01; 37(1):54-61. Hiatt RA, Sibley A, Fejerman L, Glantz S, Nguyen T, Pasick R, Palmer N, Perkins A, Potter MB, Somsouk M, Vargas RA, van 't Veer LJ, Ashworth A. PMID: 29309234.
      View in: PubMed   Mentions: 21     Fields:    Translation:Humans
    34. Family history of prostate and colorectal cancer and risk of colorectal cancer in the Women's health initiative. BMC Cancer. 2017 12 13; 17(1):848. Beebe-Dimmer JL, Yee C, Paskett E, Schwartz AG, Lane D, Palmer NRA, Bock CH, Nassir R, Simon MS. PMID: 29237415; PMCID: PMC5729427.
      View in: PubMed   Mentions: 5     Fields:    Translation:Humans
    35. Outcomes of men on active surveillance for low-risk prostate cancer at a safety-net hospital. Urol Oncol. 2017 11; 35(11):663.e9-663.e14. Osterberg EC, Palmer NRA, Harris CR, Murphy GP, Blaschko SD, Chu C, Allen IE, Cooperberg MR, Carroll PR, Breyer BN. PMID: 28826701.
      View in: PubMed   Mentions: 4     Fields:    Translation:Humans
    36. MP14-02 THE NATURAL HISTORY OF MEN ON ACTIVE SURVEILLANCE WITH LOW-RISK PROSTATE CANCER AT A SAFETY-NET, COUNTY HOSPITAL. The Journal of Urology. 2017 Apr 1; 197(4):e162-e163. Osterberg OE, Palmer PN, Harris HC, Murphy MG, Blaschko BS, Chu CC, Cooperberg CM, Carroll CP, Breyer BB. .
      View in: Publisher Site   Mentions:
    37. Abstract A53: Racial and ethnic disparities in prostate cancer survivors' perceived engagement in treatment decision making. Behavioral and Social Science. 2017 Feb 1; a53-a53. Palmer PN, Gregorich GS, Livaudais-Toman LJ, Kaplan KC. .
      View in: Publisher Site   Mentions:
    38. Disparities in barriers to follow-up care between African American and White breast cancer survivors. Support Care Cancer. 2015 Nov; 23(11):3201-9. Palmer NR, Weaver KE, Hauser SP, Lawrence JA, Talton J, Case LD, Geiger AM. PMID: 25821145; PMCID: PMC4586316.
      View in: PubMed   Mentions: 27     Fields:    Translation:Humans
    39. Familial clustering of breast and prostate cancer and risk of postmenopausal breast cancer in the Women's Health Initiative Study. Cancer. 2015 Apr 15; 121(8):1265-72. Beebe-Dimmer JL, Yee C, Cote ML, Petrucelli N, Palmer N, Bock C, Lane D, Agalliu I, Stefanick ML, Simon MS. PMID: 25754547; PMCID: PMC4457314.
      View in: PubMed   Mentions: 13     Fields:    Translation:Humans
    40. Racial and ethnic disparities in patient-provider communication, quality-of-care ratings, and patient activation among long-term cancer survivors. J Clin Oncol. 2014 Dec 20; 32(36):4087-94. Palmer NR, Kent EE, Forsythe LP, Arora NK, Rowland JH, Aziz NM, Blanch-Hartigan D, Oakley-Girvan I, Hamilton AS, Weaver KE. PMID: 25403220; PMCID: PMC4265119.
      View in: PubMed   Mentions: 60     Fields:    Translation:Humans
    41. Abstract C35: Racial disparities in barriers to follow-up care among breast cancer survivors. Cancer Treatment and Outcomes. 2014 Nov 1; c35-c35. Palmer PN, Weaver WK, Hauser HS, Talton TJ, Case CL, Lawrence LJ, Dezern DK, Geiger GA. .
      View in: Publisher Site   Mentions:
    42. Abstract A62: Post-treatment follow-up care and health-related information needs among rural breast, prostate, and colorectal cancer survivors. Behavioral and Social Science. 2014 Nov 1; a62-a62. Weaver WK, Avis AN, Palmer PN, Fitzgerald FN, Tooze TJ. .
      View in: Publisher Site   Mentions:
    43. Impact of rural residence on forgoing healthcare after cancer because of cost. Cancer Epidemiol Biomarkers Prev. 2013 Oct; 22(10):1668-76. Palmer NR, Geiger AM, Lu L, Case LD, Weaver KE. PMID: 24097196; PMCID: PMC3833446.
      View in: PubMed   Mentions: 26     Fields:    Translation:Humans
    44. Racial/Ethnic disparities in health care receipt among male cancer survivors. Am J Public Health. 2013 Jul; 103(7):1306-13. Palmer NR, Geiger AM, Felder TM, Lu L, Case LD, Weaver KE. PMID: 23678936; PMCID: PMC3682605.
      View in: PubMed   Mentions: 20     Fields:    Translation:Humans
    45. Rural-urban differences in health behaviors and implications for health status among US cancer survivors. Cancer Causes Control. 2013 Aug; 24(8):1481-90. Weaver KE, Palmer N, Lu L, Case LD, Geiger AM. PMID: 23677333; PMCID: PMC3730816.
      View in: PubMed   Mentions: 76     Fields:    Translation:Humans
    46. Transitioning from active treatment: colorectal cancer survivors' health promotion goals. Palliat Support Care. 2013 Apr; 11(2):101-9. Palmer NR, Bartholomew LK, McCurdy SA, Basen-Engquist KM, Naik AD. PMID: 23089464; PMCID: PMC3615141.
      View in: PubMed   Mentions: 11     Fields:    Translation:Humans
    47. Abstract PR07: Racial-ethnic disparities in patient-provider communication and overall perceptions of follow-up care quality among adult cancer survivors. Behavioral and Social Science. 2012 Oct 1; pr07-pr07. Palmer PN, Arora AN, Kent KE, Forsythe FL, Rowland RJ, Aziz AN, Weaver WK. .
      View in: Publisher Site   Mentions:
    48. African American prostate cancer survivors' treatment decision-making and quality of life. Patient Educ Couns. 2013 Jan; 90(1):61-8. Palmer NR, Tooze JA, Turner AR, Xu J, Avis NE. PMID: 22940374; PMCID: PMC3536017.
      View in: PubMed   Mentions: 14     Fields:    Translation:Humans
    49. Comparative effectiveness of goal setting in diabetes mellitus group clinics: randomized clinical trial. Arch Intern Med. 2011 Mar 14; 171(5):453-9. Naik AD, Palmer N, Petersen NJ, Street RL, Rao R, Suarez-Almazor M, Haidet P. PMID: 21403042; PMCID: PMC3132209.
      View in: PubMed   Mentions: 80     Fields:    Translation:Humans
    50. What is the evidence for pharmaceutical patient assistance programs? A systematic review. J Health Care Poor Underserved. 2011 Feb; 22(1):24-49. Felder TM, Palmer NR, Lal LS, Mullen PD. PMID: 21317504; PMCID: PMC3065996.
      View in: PubMed   Mentions: 22     Fields:    Translation:Humans
    Nynikka's Networks
    Concepts (140)
    Derived automatically from this person's publications.
    Explore
    _
    Co-Authors (67)
    People in Profiles who have published with this person.
    Explore
    _
    Similar People (60)
    People who share similar concepts with this person.
    Explore
    _
    Same Department
    Search Department
    _

    UCSF Profiles is managed by the UCSF Clinical and Translational Science Institute (CTSI), part of the Clinical and Translational Science Award program funded by the National Center for Advancing Translational Sciences (Grant Number UL1 TR000004) at the National Institutes of Health (NIH).

    We use cookies to operate our website. We also use cookies to analyze our site’s performance and improve your experience on our site. For more information about how we use cookies, please see our Website Terms of Use. This site is running Profiles RNS version UCSF-v3.1.0-5-g94c7c43e on PROFILES-PWEB03.

    Copyright © The Regents of the University of California.